13F Data
13F filer · CIK 1595855

Opaleye Management Inc.

BOSTON, MA · filing since Q4 2013 · last filing Aug 14, 2026
Reported value
$1.1B
+$345.0M vs prior
Positions
58
New / sold out
13 / 9
Added / reduced
15 / 13
Turnover
10.5%
buys $156.7M · sells $98.0M
Top-10 weight
64.8%

Biggest buys vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
AddedDISC MEDICINE INC+434,000+103.1%+$31.7M
NewIMMIX BIOPHARMA INC+2,345,000–+$24.2M
AddedMEIRAGTX HLDGS PLC+1,426,741+67.2%+$19.3M
NewMONTE ROSA THERAPEUTICS INC+745,000–+$18.0M
NewREPLIMUNE GROUP INC+1,384,993–+$15.3M
AddedCABALETTA BIO INC+2,483,800+180.0%+$7.7M
NewVERASTEM INC+1,800,000–+$6.9M
AddedEDITAS MEDICINE INC+1,934,933+100.4%+$6.3M
AddedBRIDGEBIO ONCOLOGY THERAPEUT+646,718+1213.8%+$4.9M
AddedLYELL IMMUNOPHARMA INC+264,928+334.9%+$3.7M
18 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Biggest sells vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
Sold outPERSPECTIVE THERAPEUTICS INC-4,675,000-100.0%$-19.5M
ReducedHARROW INC-432,230-15.3%$-18.4M
ReducedLIQUIDIA CORPORATION-97,500-3.8%$-7.8M
ReducedSANUWAVE HEALTH INC-675,127-68.8%$-6.8M
ReducedJADE BIOSCIENCES INC-282,608-66.1%$-6.3M
ReducedCG ONCOLOGY INC-77,011-81.2%$-5.5M
Sold outASSERTIO HOLDINGS INC-265,707-100.0%$-5.1M
Sold outSUTRO BIOPHARMA INC-190,671-100.0%$-4.7M
ReducedJOURNEY MED CORP-610,000-63.5%$-4.3M
ReducedQ32 BIO INC-325,228-25.9%$-4.1M
12 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2013: $127.4MQ1 2014: $135.4MQ2 2014: $116.0MQ3 2014: $128.3MQ4 2014: $197.9MQ1 2015: $215.4MQ2 2015: $251.3MQ3 2015: $203.2MQ4 2015: $239.2MQ1 2016: $160.4MQ2 2016: $149.7MQ3 2016: $191.1MQ4 2016: $169.7MQ1 2017: $200.9MQ2 2017: $239.4MQ3 2017: $282.8MQ4 2017: $312.3MQ1 2018: $349.7MQ2 2018: $386.4MQ3 2018: $393.0MQ4 2018: $268.0MQ1 2019: $361.1MQ2 2019: $328.1MQ3 2019: $276.5MQ4 2019: $509.7MQ1 2020: $377.4MQ2 2020: $495.1MQ3 2020: $511.3MQ4 2020: $765.6MQ1 2021: $680.8MQ2 2021: $602.1MQ3 2021: $535.4MQ4 2021: $471.5MQ1 2022: $322.0MQ2 2022: $221.9MQ3 2022: $242.1MQ4 2022: $287.6MQ1 2023: $333.9MQ2 2023: $418.1MQ3 2023: $307.4MQ4 2023: $376.1MQ1 2024: $458.9MQ2 2024: $437.7MQ3 2024: $599.6MQ4 2024: $571.4MQ1 2025: $449.2MQ2 2025: $494.1MQ3 2025: $707.3MQ4 2025: $757.9MQ1 2026: $759.2MQ2 2026: $1.1B
Q4 2013Q2 2026

Holdings · Q2 2026

#SecuritySharesValueWeight
1LIQUIDIA CORPORATIONCOM NEW2,447,500$195.1M17.67%
2ETON PHARMACEUTICALS INCCOM2,860,000$103.5M9.38%
3HARROW INCCOM2,400,000$101.9M9.23%
4DISC MEDICINE INCCOM855,000$62.5M5.66%
5UROGEN PHARMA LTDCOM1,439,996$53.0M4.80%
6APOGEE THERAPEUTICS INCCOM390,000$51.8M4.69%
7MEIRAGTX HLDGS PLCCOM3,550,000$48.0M4.34%
8SOL-GEL TECHNOLOGIES LTDSHS NEW500,000$37.1M3.36%
9REZOLUTE INCCOM NEW6,300,000$32.8M2.97%
10TG THERAPEUTICS INCCOM535,000$29.4M2.66%
48 more rows. Subscribe for $29/month to see every row, download the data and use the API.